PURPOSE: To determine the toxicity profile of transarterial chemoembolization (TACE) at 6 months and 1 year after treatment in patients with hepatocellular carcinoma (HCC) in a standardized oncology protocol so that TACE could be compared with systemic chemotherapeutic regimens for liver cancer. MATERIALS AND METHODS: The study was authorized by the institutional review board. Between January 2002 and January 2007, 190 patients (155 men, 35 women; median age, 65 years; age range, 18-84 years) with HCC who underwent TACE treatment were identified from a prospectively collected database. Clinical records of complete blood cell counts and chemical profiles at baseline and at 6 and 12 months after treatment were studied retrospectively. Toxicity was graded according to the common terminology criteria for adverse events (CTCAE). A transition (survival) analysis perspective was used to estimate the distribution of toxicity grades. Patient survival from the first TACE session was calculated with Kaplan-Meier analysis. RESULTS: Grade 3 or 4 toxicity 6 and 12 months, respectively, after treatment included leukocytopenia (7% and 19%); anemia (9% and 19%); thromobocytopenia (13% and 23%); prolonged activated partial thromboplastin time (8% and 18%); elevated aspartate aminotransferase (15% and 18%), alanine aminotransferase (10% and 18%), and alkaline phosphatase (8% and 18%) levels; hypoalbuminemia (10% and 19%); hyperbilirubinemia (10% and 22%); and alopecia (18%). The cumulative survival rate was 58% at 1 year, 39% at 2 years, and 29% at 3 years. These toxicity rates were considerably lower than those reported after treatment with currently used systemic chemotherapeutic agents. CONCLUSION: Study results show that TACE has a favorable long-term toxicity profile in patients with HCC. Data clearly support the role of TACE in the treatment of patients with nonresectable HCC. (c) RSNA, 2008.
PURPOSE: To determine the toxicity profile of transarterial chemoembolization (TACE) at 6 months and 1 year after treatment in patients with hepatocellular carcinoma (HCC) in a standardized oncology protocol so that TACE could be compared with systemic chemotherapeutic regimens for liver cancer. MATERIALS AND METHODS: The study was authorized by the institutional review board. Between January 2002 and January 2007, 190 patients (155 men, 35 women; median age, 65 years; age range, 18-84 years) with HCC who underwent TACE treatment were identified from a prospectively collected database. Clinical records of complete blood cell counts and chemical profiles at baseline and at 6 and 12 months after treatment were studied retrospectively. Toxicity was graded according to the common terminology criteria for adverse events (CTCAE). A transition (survival) analysis perspective was used to estimate the distribution of toxicity grades. Patient survival from the first TACE session was calculated with Kaplan-Meier analysis. RESULTS: Grade 3 or 4 toxicity 6 and 12 months, respectively, after treatment included leukocytopenia (7% and 19%); anemia (9% and 19%); thromobocytopenia (13% and 23%); prolonged activated partial thromboplastin time (8% and 18%); elevated aspartate aminotransferase (15% and 18%), alanine aminotransferase (10% and 18%), and alkaline phosphatase (8% and 18%) levels; hypoalbuminemia (10% and 19%); hyperbilirubinemia (10% and 22%); and alopecia (18%). The cumulative survival rate was 58% at 1 year, 39% at 2 years, and 29% at 3 years. These toxicity rates were considerably lower than those reported after treatment with currently used systemic chemotherapeutic agents. CONCLUSION: Study results show that TACE has a favorable long-term toxicity profile in patients with HCC. Data clearly support the role of TACE in the treatment of patients with nonresectable HCC. (c) RSNA, 2008.
Authors: G Pelletier; A Roche; O Ink; M L Anciaux; S Derhy; P Rougier; C Lenoir; P Attali; J P Etienne Journal: J Hepatol Date: 1990-09 Impact factor: 25.083
Authors: Andrew S Epstein; Eileen M O'Reilly; Maeve Lowery; Ali Shamseddine; Jinru Shia; Sally Temraz; Ashwaq Al-Olayan; Mohamed Naghy; David Kelsen; Manish A Shah; Ghassan K Abou-Alfa Journal: J Gastrointest Cancer Date: 2011-12
Authors: Andrew L Lewis; Rachel R Holden; S Ting Chung; Peter Czuczman; Timothy Kuchel; John Finnie; Susan Porter; David Foster Journal: J Mater Sci Mater Med Date: 2012-09-27 Impact factor: 3.896
Authors: Anand S Patel; Maythem Saeed; Erin J Yee; Jeffrey Yang; Gregory J Lam; Aaron D Losey; Prasheel V Lillaney; Bradford Thorne; Albert K Chin; Sheena Malik; Mark W Wilson; Xi C Chen; Nitash P Balsara; Steven W Hetts Journal: J Med Device Date: 2014-08-19 Impact factor: 0.582
Authors: Manon Buijs; Diane K Reyes; Timothy M Pawlik; Amanda L Blackford; Riad Salem; Wells A Messersmith; Colin D Weekes; Mary Mulcahy; Ihab R Kamel; Jean-Francois H Geschwind Journal: Cancer Date: 2012-11-06 Impact factor: 6.860